Cephalon Lands Option To Buy BioAssets For $30 Mil., Eying Anti-TNFs In Sciatica
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon hopes BioAssets' sciatic pain proof-of-concept study for etanercept will pave a development path for its anti-TNF.
You may also be interested in...
Deals Of The Week: Clovis/Clavis; Novartis/Incyte; Jubilant/UAB/SRI ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Clovis/Clavis; Novartis/Incyte; Jubilant/UAB/SRI ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Cephalon Reinvention Puts Biologics Front And Center
Through several acquisitions and alliances completed over the last year, Cephalon has patched together a substantial pipeline of biologic drugs, an area of business the specialty pharma is ramping up as it looks to diversify its portfolio beyond wakefulness and pain